tiprankstipranks
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
US Market
ACRV
Acrivon Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see ACRV full AI Analyst Report?

Acrivon Therapeutics, Inc. (ACRV) Stock News & Sentiment

840 Followers
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
Premium
Ratings
Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
5d ago
ACRV
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
Premium
Ratings
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
7d ago
ACRV
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
Premium
Ratings
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
7d ago
ACRV
Acrivon Highlights Positive ACR-368 Data and 2025 Results
Premium
Company Announcements
Acrivon Highlights Positive ACR-368 Data and 2025 Results
2M ago
8K
ACRV
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
Premium
Ratings
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon
3M ago
ACRV
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Premium
Company Announcements
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
3M ago
8K
ACRV
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 1/22/2026, According to Top Analysts
4M ago
ACRV
META
More ACRV News >

ACRV News on the Web

Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy
TipRanks News
Bullish
Acrivon Biosciences: Advancing ACR‑368 and ACR‑2316 Pipeline Underpins Buy Rating and Long Cash Runway
TipRanks News
Bullish
Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer
TipRanks News
Bullish
Analyst Reiterates Buy on Acrivon, Maintains $19 Price Target Amid Progress of ACR-368 Trials
TipRanks News
Bullish
Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)
TipRanks News
Bullish
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Acrivon Therapeutics Inc
GuruFocus News
Bullish
Jefferies Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
ACRV
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.25 articles
News Sentiment
This Week100%
Sector Average76%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ACRV’s Media Buzz Sentiment?
1 articles about ACRV were published this week. In an average week, 1.25 articles are published.
    What is ACRV’s weekly average amount of articles?
    In an average week, 1.25 articles about ACRV are published.
      What is ACRV’s News Sentiment?
      100% of articles about ACRV were positive this week, compared to its sector average of 76%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        CGENCompugen
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week